Gotham Therapeutics Raises $54M Series A To Target RNA-Modifying Proteins

Versant Ventures seed company Gotham Therapeutics emerges from stealth mode to develop novel class of drugs targeting RNA-modifying proteins with backing from co-leads Versant, Forbion and SR One.